Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486247 | 1.00 | GSK3B (0.56) | GSK3BPRKCICYP2D6CYP1A2 | |
| SCHEMBL2489423 | 0.84 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2489424 | 0.84 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2491338 | 0.84 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2491335 | 0.84 | GSK3B (0.52) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2488361 | 0.83 | GSK3B (0.51) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2489065 | 0.83 | GSK3B (0.51) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2489067 | 0.83 | GSK3B (0.51) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2488366 | 0.83 | GSK3B (0.51) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL2485921 | 0.82 | GSK3B (0.57) | GSK3BCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCI 884/4885CYP2D6 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.